Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15

C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia

Authors Chang CH, Lane HY, Liu CY, Cheng PC, Chen SJ, Lin CH

Received 15 July 2019

Accepted for publication 26 August 2019

Published 10 September 2019 Volume 2019:15 Pages 2621—2627


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Yuping Ning

Chun-Hung Chang,1–3 Hsien-Yuan Lane,1,2,4,5,* Chieh-Yu Liu,6 Po-Chih Cheng,6 Shaw-Ji Chen,7,8 Chieh-Hsin Lin1,4,9,*

1Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan; 2Department of Psychiatry & Brain Disease Research Center, China Medical University Hospital, Taichung, Taiwan; 3An Nan Hospital, China Medical University, Tainan, Taiwan; 4Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; 5Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung, Taiwan; 6Biostatistical Consulting Laboratory, Department of Speech Language Pathology and Audiology, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan; 7Department of Psychiatry, Mackay Memorial Hospital Taitung Branch, Taitung, Taiwan; 8Department of Medicine, Mackay Medical College, New Taipei, Taiwan; 9Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan

*These authors contributed equally to this work

Correspondence: Hsien-Yuan Lane
Department of Psychiatry, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan
Email [email protected]

Chieh-Hsin Lin
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, No 123, Dapi Road, Niaosong District, Kaohsiung 833, Taiwan
Tel +886 7 731 7123 Ext 8753
Fax +886 7 732 6817
Email [email protected]

Background: Numerous studies have demonstrated an association between C-reactive protein (CRP) levels and schizophrenia. However, the findings on psychotic severity and cognition remain inconsistent. The relationship between CRP and formal thought disorder in subdomains remains unclear.
Methods: We enrolled stable patients (defined as those who had no treatment changes during the 4-week period before evaluation) with a diagnosis of schizophrenia or schizoaffective disorder, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. We used the 30-item Thought and Language Disorder (TALD) scale to evaluate thought and language dysfunction over four subscales. We assessed psychotic symptoms using the Positive and Negative Syndrome Scale (PANSS). We collected fasting venous blood and measured plasma CRP levels.
Results: We enrolled 60 patients with schizophrenia. All patients received TALD and PANSS evaluation, and 33 of them had their CRP levels checked. The multivariate regression analysis indicated that CRP levels were significantly associated with the total score on the TALD (t=2.757, P=0.010) and the TALD Objective Positive subscale (t=2.749, P=0.011), after sex, age, duration of illness (in years), and use of atypical antipsychotics were adjusted for. Additionally, CRP was significantly associated with the PANSS positive subscale (t=2.102, P=0.045). A significantly positive correlation was observed between the total scores on the TALD scale and PANSS (ρ =0.751, P<0.001).
Conclusion: Our results suggest that abnormal CRP levels are significantly associated with formal thought and language dysfunction in the Objective Positive subdomain and positive psychotic symptoms.

Keywords: C-reactive protein, formal thought disorder, schizophrenia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]